Bortezomib for consolidation therapy after autologous stem cell transplantation for the treatment of multiple myeloma
Status Suspended
Decision Selected
Process STA pre-2018
Referral date 01 May 2012
Topic area
  • Cancer
  • Surgical procedures

Scoped as part of Batch 22

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
7 November 2014

The Institute has now been informed by the manufacturer that it will no longer be pursuing a licensing application for bortezomib in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

20 July 2012 Please note that following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established.

For further information on our processes and methods, please see our CHTE processes and methods manual